Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin’s lymphomas

  • H. Kamata
  • S. Mitani
  • M. Fujiwara
  • N. Aoki
  • S. Okada
  • S. Mori


To clarify whether p53 mutation could be involved in the pathogenesis of various subtypes of lymphoma, we investigated 62 Japanese cases of non-Hodgkin’s lymphomas (NHLs) for p53 gene mutations and their relationship with the expression of p53 protein. Mutations in exons 5–9 of the p53 gene were screened for using the non-isotopic RNase cleavage assay (NIRCA) and confirmed by direct sequencing, followed by immunohistochemical analysis for p53 protein. Missense and/or nonsense mutations of p53 were detected in 3 (10.7%) of 28 diffuse large B-cell lymphomas (DLBLs) and 2 (15.4%) of 13 T-cell NHLs (15.4%). A single missense mutation at codon 157 (Val to Phe) in exon 5 and at codon 273 (Arg to Pro) in exon 8 was found respectively in 2 DLBLs and in one peripheral T-cell lymphoma (unspecified). In these 3 cases harbouring a missense mutation, overexpression of p53 protein was observed in more than 80% of tumour cells. Double transversion mutations comprising of a missense mutation at codon 167 (Gln to His) in exon 5 and a nonsense mutation at codon 183 (Ser to stop codon) in exon 5 were detected in one DLBL that had apparently transformed from follicular lymphoma and in one advanced adult T-cell lymphoma (ATL). In these two cases harbouring p53 nonsense mutation, no cells positive for p53 protein immunostaining were detected, as well as lymphomas without p53 mutation.

Key words

p53 Non-Hodgkin’s lymphoma Non-isotopic RNase cleavage assay 


  1. 1.
    Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81–37CrossRefPubMedGoogle Scholar
  2. 2.
    Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–31CrossRefPubMedGoogle Scholar
  3. 3.
    Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629–34CrossRefPubMedGoogle Scholar
  4. 4.
    Lamb P, Crawford LV (1986) Characterization of the human p53 gene. Mol Cell Biol 6:1379–385PubMedGoogle Scholar
  5. 5.
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–878PubMedGoogle Scholar
  6. 6.
    Hollstein M, Shomer B, Greenblatt M et al (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24:141–46CrossRefPubMedGoogle Scholar
  7. 7.
    Brachmann RK, Yu K, Eby Y et al (1998) Genetics selection of intragenic suppressor mutations that reverse the effects of common p53 cancer mutations. EMBO J 17:1847–859CrossRefPubMedGoogle Scholar
  8. 8.
    Imamura J, Miyoshi I, Koeffler HP (1994) p53 in hematologic malignancies. Blood 84:2412–421PubMedGoogle Scholar
  9. 9.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutation in human cancers. Science 253:49–3CrossRefPubMedGoogle Scholar
  10. 10.
    Nigro JM, Baker SJ, Preisinger AC et al (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705–08CrossRefPubMedGoogle Scholar
  11. 11.
    Bhatia KG, Gutierrez MI, Huppi K, Siwarski D (1992) The pattern of p53 mutations in Burkitt’s lymphoma differs from that of solid tumor. Cancer Res 52:4273–276PubMedGoogle Scholar
  12. 12.
    Gaidano G, Ballerini P, Gong JZ et al (1991) p53 mutation in human lymphoid malignancies: association with Burkitt’s lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 88:5413–417CrossRefPubMedGoogle Scholar
  13. 13.
    Ichikawa A, Hotta T, Takagi N et al (1992) Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701–707PubMedGoogle Scholar
  14. 14.
    Soussi T, Caron de Fromentel C, May P (1990) Structural aspect of the p53 protein in relation to gene evolution. Oncogene 5:945–52PubMedGoogle Scholar
  15. 15.
    Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453–56CrossRefPubMedGoogle Scholar
  16. 16.
    Pignon JM, Vinatier I, Fanen P et al (1994) Exhaustive analysis of the 53 gene coding sequence by denaturing gradient gel electrophoresis: application to the detection of point mutations in acute leukemia. Hum Mutat 3:126–32CrossRefPubMedGoogle Scholar
  17. 17.
    Preudhomme C, Fenaux P (1997) The clinical significance of mutations of the p53 suppressor gene in haematological malignancies. Br J Hematol 98: 502–11CrossRefGoogle Scholar
  18. 18.
    Cesarman E, Chadburn A, Inghirami G et al (1992) Structural and functional analysis of oncogene and tumor suppressor genes in adult T-cell leukemia /lymphoma shows frequent p53 mutations. Blood 80:3205–216PubMedGoogle Scholar
  19. 19.
    Sakasita A, Hattori T, Miller CW et al (1992) Mutations of the p53 gene in adult T cell leukemia. Blood 79:477–80Google Scholar
  20. 20.
    Harris NL, Jaffe ES, Diebold J et al (1999) The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues. Ann Oncol 10:1419–432CrossRefPubMedGoogle Scholar
  21. 21.
    Shibata DK, Arnheim N, Martin WJ (1988) Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction. J Exp Med 167:225–30CrossRefPubMedGoogle Scholar
  22. 22.
    Myers RM, Larin Z, Maniatis T (1985) Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA-DNA duplexes. Science 230:1242–246CrossRefPubMedGoogle Scholar
  23. 23.
    Winter E, Yamamoto F, Almohuera C, Perucho M (1985) A method to detect and characterize point mutation in transcribed genes. Proc Natl Acad Sci U S A 82:7575–579CrossRefPubMedGoogle Scholar
  24. 24.
    Chilosi M, Doglioni C, Magalini A et al (1996) p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin’s lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 88:4012–020PubMedGoogle Scholar
  25. 25.
    Maestoro R, Gloghini A, Doglioni C et al (1997) Human non-Hodgkin’s lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclindependent kinase inhibitor p21. Blood 89:2523–528Google Scholar
  26. 26.
    Adamson DJA, Thompson WD, Dawson AA et al (1995) p53 mutation and expression in lymphoma. Br J Cancer 72:150–54PubMedGoogle Scholar
  27. 27.
    Klumb CE, Furtado DR, de Resende LMM et al (2003) DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin’s lymphomas: prognostic implications. Eur J Haematol 71:81–0CrossRefPubMedGoogle Scholar
  28. 28.
    Ichikawa A, Kinoshita T, Watanabe T et al (1997) Mutation of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–34CrossRefPubMedGoogle Scholar
  29. 29.
    Sanche-Beato M, Saez AI, Navas IC et al (2001) Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alteration in p53, p16, and p27. Am J Pathol 159:205–13Google Scholar
  30. 30.
    Leroy K, Haioun C, Lepage E et al (2002) p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13:1108–115CrossRefPubMedGoogle Scholar
  31. 31.
    Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor Suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346–55CrossRefPubMedGoogle Scholar
  32. 32.
    Koduru PR, Raju K, Vadmal V et al (1997) Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood 90:4078–091PubMedGoogle Scholar
  33. 33.
    Preudhomme C, Dervite I, Wattel E et al (1995) Clinical significance of p53 mutations in newly diagnosed Burkitt’s lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 13:812–20PubMedGoogle Scholar
  34. 34.
    Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Natl Rev Cancer 1:233–39CrossRefGoogle Scholar
  35. 35.
    Gulley ML, Burton MP, Allred DC et al (1998) Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum Pathol 29:252–59CrossRefPubMedGoogle Scholar
  36. 36.
    Sander CA, Yano T, Clark HM et al (1993) p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994–004PubMedGoogle Scholar
  37. 37.
    Lo Coco F, Gaidano G, Louie DC et al (1993) p53 mutation are associated with histologic transformation of follicular lymphoma. Blood 82:2289–295PubMedGoogle Scholar
  38. 38.
    Du MQ, Peng HZ, Singh N et al (1995) The accumulation of p53 abnormality is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587–593PubMedGoogle Scholar
  39. 39.
    Petit B, Leroy K, Kanavaros P et al (2001) Expression of p53 protein in T-and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. Hum Pathol 32:196–04CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • H. Kamata
    • 1
  • S. Mitani
    • 2
  • M. Fujiwara
    • 3
  • N. Aoki
    • 4
  • S. Okada
    • 5
  • S. Mori
    • 4
  1. 1.Laboratory of Veterinary MicrobiologyCollege of Bioresource Sciences Nihon UniversityKanagawaJapan
  2. 2.Center for Professional EducationKanagawa Prefectural University of Human ServiceKanagawaJapan
  3. 3.Division of PathologyThe Japanese Red Cross Medical CenterTokyoJapan
  4. 4.Department of PathologyTeikyo University School of MedicineTokyoJapan
  5. 5.Department of PathologyAgeo Medical LaboratorySaitamaJapan

Personalised recommendations